

Supplementary Table 1

Subgroup analysis of B01 subgroups and primary outcome of discontinuity

Unadjusted OR (95%CI, p-value)						Adjusted OR (95%CI, p-value)							
	Aspirin and other antiplatelet agents: NO2BA		Warfarin + NOACs: B01AE B01AF		Warfarin + NOACs: B01AA B01AE B01AF			Aspirin and other antiplatelet agents: NO2BA		Warfarin + NOACs: B01AE B01AF		Warfarin + NOACs: B01AA B01AE B01AF	
	Antithrombotics (B01) (n=13,684)	01 B01AC (n=7613)	Warfarin: B01 AA (n=1267)	NOACs: B01AE B01AF (n=235)	NOACs: B01AA B01AE B01AF (n=1475)		Antithrombotics (B01) (n=13,684)	01 B01AC (n=7613)	Warfarin: B01 AA (n=1267)	NOACs: B01AE B01AF (n=235)	NOACs: B01AA B01AE B01AF (n=1475)		
Hospitalised v non-hospitalised	0.95 (0.82,1.10), p=0.49	1.33 (1.15,1.53) p<0.001	1.11 (0.82,1.50) p=0.49	1.05 (0.47,2.35) p=0.90	1.09 (0.78,1.53) p=0.61	Hospitalised v non-hospitalised	0.95 (0.81,1.11), p=0.49	1.30 (1.12,1.52) p<0.001	0.95 (0.69,1.30) p=0.74	1.01 (0.43,2.34) p=0.99	0.97 (0.68,1.39) p=0.88		
Age (years)	1.02 (1.01,1.03) , p<0.001	1.03 (1.02,1.04) p<0.001	1.04 (1.01,1.06) p<0.001	1.00 (0.94,1.05) p=0.91	1.04 (1.01,1.06) p<0.001	Age (years)	1.03 (1.02,1.04) , p<0.001	1.03 (1.02,1.04) p<0.001	1.05 (1.02,1.07) p<0.001	1.00 (0.94,1.06) p=0.96	1.04 (1.02,1.07) p<0.001		
Gender: Female v Male	1.02 (0.89,1.17), p=0.79	0.94 (0.83,1.08) p=0.39	0.91 (0.68,1.23) p=0.55	1.10 (0.53,2.31) p=0.80	1.22 (0.88,1.69) p=0.23	Gender: Female v Male	1.00 (0.87,1.15), p=0.99	0.88 (0.76,1.01) p=0.07	0.81 (0.58,1.11) p=0.19	1.24 (0.56,2.73) p=0.59	1.18 (0.83,1.67) p=0.36		
Private v Public (GMS/DVC) patients	5.10 (4.31,6.04), p<0.001	3.89 (3.28,4.63) p<0.001	3.87 (2.55,5.87) p<0.001	3.72 (1.44,9.58) p=0.01	4.05 (2.64,6.23) p<0.001	Private v Public (GMS/DVC) patients	5.35 (4.50,6.34), p<0.001	4.26 (3.57,5.08) p<0.001	4.33 (2.81,6.67) p<0.001	4.42 (1.62,12.02) p<0.001	4.38 (2.81,6.82) p<0.001		
Number of repeat drug classes	0.99 (0.98,1.01), p=0.56	1.01 (0.99,1.03) p=0.26	1.01 (0.97,1.05) p=0.67	0.99 (0.90,1.10) p=0.87	0.98 (0.93,1.02) p=0.27	Number of repeat drug classes	0.99 (0.97,1.01), p=0.28	1.00 (0.98,1.02) p=0.86	1.01 (0.97,1.06) p=0.52	0.95 (0.85,1.07) p=0.38	0.97 (0.92,1.02) p=0.23		
Charlson score (>=1 v0)	0.93 (0.80,1.07), p=0.31	0.84 (0.73,0.97) p=0.02	0.93 (0.69,1.26) p=0.65	0.96 (0.46,2.00) p=0.91	1.04 (0.74,1.46) p=0.81	Charlson score (>=1 v0)	0.94 (0.80,1.09), p=0.41	0.81 (0.70,0.95) p=0.01	0.84 (0.61,1.16) p=0.29	1.07 (0.50,2.31) p=0.87	1.00 (0.70,1.43) p=1.00		
No of consultations in enrolment period	1.00 (0.99,1.01), p=0.62	1.01 (1.00,1.01) p=0.11	1.00 (0.99,1.02) p=0.52	1.02 (0.98,1.06) p=0.35	1.00 (0.98,1.01) p=0.68	No of consultations in enrolment period	1.00 (0.99,1.01), p=0.63	1.01 (1.00,1.01) p=0.23	1.00 (0.99,1.02) p=0.48	1.03 (0.99,1.07) p=0.15	1.00 (0.98,1.02) p=0.98		

Adjusted model includes gender, age, insurance type, Charlson Index, number of repeat drugs, number of consultations in the enrolment period

GMS: General Medical Services

DVC: Doctor Visit Card

OR: odds ratio

CI: confidence interval